AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25387655 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong Acid Electrolyzed Water (SAEW)
Number of subjects: 44
Study 25387655 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 44
Study 23506518 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and postoperative physical therapy
Number of subjects: 351
Study 23506518 — intervention group
Group type: COMPARATOR
Intervention: Standardized physical‐therapy regimen
Number of subjects: 351
Study 21153559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (Interpersonal Psychotherapy based intervention)
Number of subjects: 54
Study 21153559 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study 19496829 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenothiazines
Number of subjects: 13
Study 19496829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 19496829 — intervention group
Group type: COMPARATOR
Intervention: Other active agents
Number of subjects: 13
Study 19496829 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 13
Study 16861091 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg QD
Number of subjects: 395
Study 16861091 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 250 mg QD
Number of subjects: 395
Study 16861091 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil (combined group)
Number of subjects: 395
Study 16861091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study 12644518 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Dye strap
Number of subjects: 0
Study 11156125 — intervention group
Group type: EXPERIMENTAL
Intervention: Open heart surgery (OHS)
Number of subjects: 171
Study 11156125 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 171
Study 9291281 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy with standardized cat dander extract
Number of subjects: 28
Study 9291281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 7686705 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HTS) 7.5% combined with hydroxyethylstarch (HAES)
Number of subjects: 41
Study 3105558 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole 5 mg/d
Number of subjects: 38
Study 3105558 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole 10 mg/d
Number of subjects: 38
Study 3105558 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole 20 mg/d
Number of subjects: 38
Study 3105558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 29587288 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sodium thiosulfate (IV STS) 12.5 g during the last HD hour twice weekly for 6 months
Number of subjects: 50
Study 29587288 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 50
Study 29587288 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sodium thiosulfate (IV STS)
Number of subjects: 50
Study 27510000 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of social marketing theory and health belief model program
Number of subjects: 92
Study 27510000 — intervention group
Group type: COMPARATOR
Intervention: Normal services (Control)
Number of subjects: 92
Study 25373724 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) combined with standard treatment
Number of subjects: 31
Study 25373724 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS combined with standard treatment
Number of subjects: 31
Study 22575567 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)-ketamine IV doses starting at 1.5 mg with 1.5-mg increments
Number of subjects: 22
Study 22575567 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)-ketamine IV doses
Number of subjects: 22
Study 22575567 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)-ketamine pharmacokinetics
Number of subjects: 22
Study 22575567 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)-ketamine pharmacodynamics
Number of subjects: 22
Study 20413121 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse clinic combined with telephone follow-up
Number of subjects: 0
Study 20413121 — intervention group
Group type: COMPARATOR
Intervention: Control group (nurse clinic only)
Number of subjects: 0
Study 17390761 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl, 180 mg
Number of subjects: 0
Study 17390761 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine, 5 mg
Number of subjects: 0
Study 16140701 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic removal (surgery)
Number of subjects: 60
Study 16140701 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 60
Study 12010586 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate-high-glycaemic index (GI)
Number of subjects: 35
Study 12010586 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate-low-glycaemic index (GI)
Number of subjects: 35
Study 12010586 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate-high-monounsaturated fat (MUFA)
Number of subjects: 35
Study 9449869 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic exploration of common bile duct (LECBD)
Number of subjects: 80
Study 9449869 — intervention group
Group type: COMPARATOR
Intervention: Postoperative endoscopic retrograde cholangiography (ERCP)
Number of subjects: 80
Study 7667377 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 6
Study 7667377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2611075 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. diazepam 0.15 mg kg‐1
Number of subjects: 26
Study 2611075 — intervention group
Group type: COMPARATOR
Intervention: i.v. midazolam 0.07 mg kg‐1
Number of subjects: 26
Study 993925 — intervention group
Group type: EXPERIMENTAL
Intervention: High rate of intravenous infusion (10.3 ml/kg/hr)
Number of subjects: 20
Study 993925 — intervention group
Group type: COMPARATOR
Intervention: Low rate of intravenous infusion (3.6 ml/kg/hr)
Number of subjects: 20
Study 31935353 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric interdisciplinary home rehabilitation for a maximum of 10 weeks
Number of subjects: 205
Study 31935353 — intervention group
Group type: COMPARATOR
Intervention: Inhospital geriatric care
Number of subjects: 205
Study 30827767 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Universal rotary files (Dentsply Maillefer, Ballaigues, Switzerland)
Number of subjects: 150
Study 30827767 — intervention group
Group type: EXPERIMENTAL
Intervention: OneShape rotary files (Micro‐Mega, Besancon, France)
Number of subjects: 150
Study 30827767 — intervention group
Group type: EXPERIMENTAL
Intervention: WaveOne reciprocal system (Dentsply Maillefer, Ballaigues, Switzerland)
Number of subjects: 150
Study 30827767 — intervention group
Group type: COMPARATOR
Intervention: Hand files (control 2)
Number of subjects: 150
Study 30827767 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control 1)
Number of subjects: 150
Study 27349705 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin plus ezetimibe (target LDL-C <70mg/dL)
Number of subjects: 1734
Study 27349705 — intervention group
Group type: COMPARATOR
Intervention: Pitavastatin monotherapy (target LDL-C 90-100mg/dL)
Number of subjects: 1734
Study 26944583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma (CAP) applied for 90 seconds in three sessions
Number of subjects: 20
Study 25000163 — intervention group
Group type: EXPERIMENTAL
Intervention: TheraBite® Jaw Motion Rehabilitation System (TB)
Number of subjects: 96
Study 25000163 — intervention group
Group type: COMPARATOR
Intervention: Standard physical therapy (PT) exercises
Number of subjects: 96
Study 25000163 — intervention group
Group type: COMPARATOR
Intervention: Both TB and standard PT
Number of subjects: 96
Study 21996058 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (EX) - attended exercise facility three times/week for 52 weeks, daily jumping exercises at home, calcium supplementation.
Number of subjects: 39
Study 21996058 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) - continued usual care, calcium supplementation.
Number of subjects: 39
Study 21996058 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (EX)
Number of subjects: 39
Study 21996058 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 39
Study 20403926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive management of screen-detected patients
Number of subjects: 18
Study 20403926 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 18
Study 17629159 — intervention group
Group type: EXPERIMENTAL
Intervention: Colposcopists' agreement with consensus diagnoses
Number of subjects: 72
Study 17629159 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of ECC
Number of subjects: 72
Study 17629159 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing agreement
Number of subjects: 72
Study 16216024 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting Balloon (CB) angioplasty followed by Sr/Y‐90 beta‐brachytherapy
Number of subjects: 100
Study 16216024 — intervention group
Group type: COMPARATOR
Intervention: Standard Balloon (SB) angioplasty followed by Sr/Y‐90 beta‐brachytherapy
Number of subjects: 100
Study 11966923 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush (Braun Oral‐B Plaque Remover 3‐D)
Number of subjects: 40
Study 11966923 — intervention group
Group type: COMPARATOR
Intervention: Manual soft toothbrush (Oral‐B Squish‐grip brush)
Number of subjects: 40
Study 10195511 — intervention group
Group type: COMPARATOR
Intervention: Propofol (50 microg x kg(‐1) x min(‐1))
Number of subjects: 60
Study 10195511 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital (40 microg x kg(‐1) x min(‐1))
Number of subjects: 60
Study 10195511 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital (29.4 +/‐ 2.7 microg x kg(‐1) x min(‐1))
Number of subjects: 60
Study 10195511 — intervention group
Group type: COMPARATOR
Intervention: Propofol (36.8 +/‐ 15.9 microg x kg(‐1) x min(‐1))
Number of subjects: 60
Study 10195511 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital and Propofol
Number of subjects: 60
Study 7773730 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 22
Study 7773730 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 22
Study 1639941 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg cetrorelix
Number of subjects: 30
Study 1639941 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg cetrorelix
Number of subjects: 30
Study 1639941 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg cetrorelix
Number of subjects: 30
Study 1639941 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg cetrorelix
Number of subjects: 30
Study 1639941 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg cetrorelix
Number of subjects: 30
Study 1639941 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg cetrorelix)
Number of subjects: 30
Study 6089307 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (40 mg daily)
Number of subjects: 22
Study 6089307 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (40 mg daily)
Number of subjects: 22
Study 6089307 — intervention group
Group type: EXPERIMENTAL
Intervention: Both enalapril and lisinopril
Number of subjects: 22
Study 6089307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31831056 — intervention group
Group type: EXPERIMENTAL
Intervention: Gantenerumab 1200 mg every 4 weeks
Number of subjects: 67
Study 31831056 — intervention group
Group type: COMPARATOR
Intervention: Gantenerumab 225 mg
Number of subjects: 67
Study 29747252 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐UPPP combined with tongue base radiofrequency ablation (experimental group)
Number of subjects: 62
Study 29747252 — intervention group
Group type: COMPARATOR
Intervention: H‐UPPP (control group)
Number of subjects: 62
Study 26792672 — intervention group
Group type: EXPERIMENTAL
Intervention: School feeding programme group (standard government programme)
Number of subjects: 116
Study 26792672 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-grown school feeding (standard programme + innovative pilot project)
Number of subjects: 116
Study 26792672 — intervention group
Group type: COMPARATOR
Intervention: Control group (intervention delayed by at least 3 years)
Number of subjects: 116
Study 28726022 — intervention group
Group type: EXPERIMENTAL
Intervention: On-medication condition
Number of subjects: 4
Study 28726022 — intervention group
Group type: COMPARATOR
Intervention: Off-medication condition
Number of subjects: 4
Study 23472142 — intervention group
Group type: EXPERIMENTAL
Intervention: DHI Score ≥50
Number of subjects: 88
Study 23472142 — intervention group
Group type: COMPARATOR
Intervention: DHI Score <50
Number of subjects: 88
Study 22031049 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste used at night after demineralization episodes
Number of subjects: 12
Study 22031049 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste used in the morning before demineralization episodes
Number of subjects: 12
Study 22031049 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoride placebo toothpaste
Number of subjects: 12
Study 19483453 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal injection of 0.25% bupivacaine (40 ml) and 20 ml in 4 ports (5 ml each)
Number of subjects: 40
Study 19483453 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 19483453 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal injection of 0.25% bupivacaine
Number of subjects: 40
Study 18694194 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-STAR disease management program integrated with an online patient portal
Number of subjects: 331
Study 15277913 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal Laryngeal Mask Airway (PLMA)
Number of subjects: 150
Study 15277913 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Tube Suction (LTS)
Number of subjects: 150
Study 11504277 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone extended-release (ER) formulation, 30 mg once daily for 7 days
Number of subjects: 36
Study 11504277 — intervention group
Group type: COMPARATOR
Intervention: Buspirone immediate-release (IR) formulation, 15 mg twice daily for 7 days
Number of subjects: 36
Study 11504277 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone extended-release (ER) formulation
Number of subjects: 36
Study 11504277 — intervention group
Group type: COMPARATOR
Intervention: Buspirone immediate-release (IR) formulation
Number of subjects: 36
Study 9489934 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine cigarette (0.8 mg nicotine)
Number of subjects: 96
Study 9489934 — intervention group
Group type: COMPARATOR
Intervention: Sham cigarette
Number of subjects: 96
Study 9489934 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine tablet
Number of subjects: 96
Study 9489934 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 96
Study 9489934 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction of receiving nicotine
Number of subjects: 96
Study 9489934 — intervention group
Group type: COMPARATOR
Intervention: Instruction of receiving sham
Number of subjects: 96
Study 7531423 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 60
Study 7531423 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 60
Study 7531423 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 60
Study 7531423 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 2336928 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5, 1.0, 2.0 or 4.0% D-timolol
Number of subjects: 0
Study 2336928 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% L-timolol
Number of subjects: 0
Study 2336928 — intervention group
Group type: COMPARATOR
Intervention: 4.0% D-timolol
Number of subjects: 0
Study 7212475 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075 mg/kg dose of verapamil
Number of subjects: 20
Study 7212475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7212475 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg dose of verapamil (open-label phase)
Number of subjects: 20
Study 30889043 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute running (70% V˙O2max) followed by a standardized meal (1170 kcal, 43% CHO, 17% PRO, 40% fat)
Number of subjects: 15
Study 30889043 — intervention group
Group type: COMPARATOR
Intervention: Control (rest) followed by a standardized meal (1170 kcal, 43% CHO, 17% PRO, 40% fat)
Number of subjects: 15
Study 28768334 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help (GSH-I)
Number of subjects: 178
Study 28768334 — intervention group
Group type: COMPARATOR
Intervention: Individual face-to-face cognitive behavioral therapy (CBT)
Number of subjects: 178
Study 23269112 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Coach and Office Staff Support Intervention
Number of subjects: 280
Study 23269112 — intervention group
Group type: COMPARATOR
Intervention: Control Group (noncompliers)
Number of subjects: 280
Study 23269112 — intervention group
Group type: COMPARATOR
Intervention: Intention-to-treat analysis
Number of subjects: 280
Study 23419791 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT)
Number of subjects: 33
Study 23419791 — intervention group
Group type: COMPARATOR
Intervention: Control Treatment (CT)
Number of subjects: 33
Study 21856778 — intervention group
Group type: COMPARATOR
Intervention: Local Anaesthetic Infiltration (LAI)
Number of subjects: 52
Study 21856778 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Rectus Sheath Block (RSB)
Number of subjects: 52
Study 19221905 — intervention group
Group type: EXPERIMENTAL
Intervention: Tone burst stimuli measuring summating potentials (SP)
Number of subjects: 2717
Study 19221905 — intervention group
Group type: COMPARATOR
Intervention: Click evoked summating potential versus action potential ratio (SP/AP)
Number of subjects: 2717
Study 17124239 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-piece acrylic hydrophobic IOL
Number of subjects: 74
Study 17124239 — intervention group
Group type: COMPARATOR
Intervention: One-piece acrylic hydrophobic IOL
Number of subjects: 74
Study 15016251 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental gingivitis (test quadrant)
Number of subjects: 96
Study 15016251 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral quadrant)
Number of subjects: 96
Study 11150970 — intervention group
Group type: EXPERIMENTAL
Intervention: D90A CuZn-SOD mutation patients
Number of subjects: 8
Study 11150970 — intervention group
Group type: COMPARATOR
Intervention: Multiple sclerosis patients
Number of subjects: 8
Study 11150970 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 8
Study 9444470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sounds produced by familiar natural instruments (violin, flute, guitar, drum)
Number of subjects: 0
Study 9444470 — intervention group
Group type: COMPARATOR
Intervention: Sounds played backwards (less recognizable)
Number of subjects: 0
Study 9444470 — intervention group
Group type: EXPERIMENTAL
Intervention: Both familiar and unfamiliar sounds
Number of subjects: 0
Study 7910838 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine with interferon-alpha (IFN-alpha) (n = 25)
Number of subjects: 45
Study 7910838 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine alone (n = 20)
Number of subjects: 45
Study 7910838 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Zidovudine and IFN-alpha, Zidovudine alone)
Number of subjects: 45
Study 7910838 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine and IFN-alpha
Number of subjects: 45
Study 7910838 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine alone
Number of subjects: 45
Study 2293257 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 40
Study 2293257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 229547 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in polyunsaturated acids
Number of subjects: 10
Study 229547 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in oleic acids
Number of subjects: 10
Study 229547 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 10
Study 31782930 — intervention group
Group type: COMPARATOR
Intervention: Vigorous-intensity continuous training (VICT)
Number of subjects: 52
Study 31782930 — intervention group
Group type: COMPARATOR
Intervention: Whole-body Tabata
Number of subjects: 52
Study 31782930 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control (CTL)
Number of subjects: 52
Study 31040197 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term (LT) methimazole treatment (n = 24)
Number of subjects: 66
Study 31040197 — intervention group
Group type: COMPARATOR
Intervention: Short-term (ST) methimazole treatment (n = 24)
Number of subjects: 66
Study 28213368 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice daily
Number of subjects: 17113
Study 28213368 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg twice daily
Number of subjects: 17113
Study 25462662 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime substance users (excluding cannabis)
Number of subjects: 242
Study 25462662 — intervention group
Group type: EXPERIMENTAL
Intervention: Thirty day drug use frequency for opiates and alcohol
Number of subjects: 242
Study 25462662 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime history of non-clinical substance use
Number of subjects: 242
Study 23627650 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 60 µg alprostadil over 3 weeks
Number of subjects: 33
Study 23627650 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion over 3 weeks
Number of subjects: 33
Study 21266651 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 436
Study 21266651 — intervention group
Group type: COMPARATOR
Intervention: Standard home blood glucose monitoring
Number of subjects: 436